202 related articles for article (PubMed ID: 9854476)
1. Classification of acute myeloid leukaemia in trephine biopsies with special reference to lactoferrin.
Al Safadi L; Köhler G; Schaefer HE
Anticancer Res; 1998; 18(5B):3677-84. PubMed ID: 9854476
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category.
Ghannadan M; Wimazal F; Simonitsch I; Sperr WR; Mayerhofer M; Sillaber C; Hauswirth AW; Gadner H; Chott A; Horny HP; Lechner K; Valent P
Am J Clin Pathol; 2003 May; 119(5):663-71. PubMed ID: 12760284
[TBL] [Abstract][Full Text] [Related]
3. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
[TBL] [Abstract][Full Text] [Related]
4. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic significance of serum measurements of lactoferrin, lysozyme and myeloperoxidase in acute myeloid leukemia (AML): recognition of a new variant, high-lactoferrin AML.
Oberg G; Dahl R; Ellegaard J; Sundström C; Vaeth M; Venge P
Eur J Haematol; 1987 Feb; 38(2):148-55. PubMed ID: 3036571
[TBL] [Abstract][Full Text] [Related]
6. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis.
Klobusicka M; Kusenda J; Babusikova O
Neoplasma; 2005; 52(3):211-8. PubMed ID: 15875082
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow trephine findings in acute myeloid leukaemia with multilineage dysplasia.
Ngo N; Lampert IA; Naresh KN
Br J Haematol; 2008 Feb; 140(3):279-86. PubMed ID: 17973948
[TBL] [Abstract][Full Text] [Related]
8. Assessment of monocytic component in acute myelomonocytic and monocytic/monoblastic leukemias by a chemiluminescent assay.
da Fonseca LM; Brunetti IL; Campa A; Catalani LH; Calado RT; Falcão RP
Hematol J; 2003; 4(1):26-30. PubMed ID: 12692517
[TBL] [Abstract][Full Text] [Related]
9. [Correlation of immunophenotype to cytogenetics and clinical features of adult acute myeloid leukemia].
Wang XB; Zheng JE; Gu JX; Yao JX; Yang J; Liu J; Li XQ; He YL; Yu JM; Wei J; Liu ZP; Huang SA
Ai Zheng; 2005 Jun; 24(6):667-71. PubMed ID: 15946475
[TBL] [Abstract][Full Text] [Related]
10. Intracellular markers in acute myeloid leukemia diagnosis.
Koníková E; Glasová M; Kusenda J; Babusíková O
Neoplasma; 1998; 45(5):282-91. PubMed ID: 9921916
[TBL] [Abstract][Full Text] [Related]
11. Expression of poliovirus receptor-related proteins PRR1 and PRR2 in acute myeloid leukemia: first report of surface marker analysis, contribution to diagnosis, prognosis and implications for future therapeutical strategies.
Graf M; Reif S; Hecht K; Kroell T; Nuessler V; Schmetzer H
Eur J Haematol; 2005 Dec; 75(6):477-84. PubMed ID: 16313259
[TBL] [Abstract][Full Text] [Related]
12. CD79 alpha expression in acute myeloid leukemia. High frequency of expression in acute promyelocytic leukemia.
Arber DA; Jenkins KA; Slovak ML
Am J Pathol; 1996 Oct; 149(4):1105-10. PubMed ID: 8863659
[TBL] [Abstract][Full Text] [Related]
13. [Clinical analysis of HLA-DR-negative non-M3 AML].
Mori H; Sakai H; Sanada M; Shimamoto K; Sasaki S; Azuma R; Higuchi T; Harada H; Niikura H; Omine M; Fujita K; Takahashi N
Rinsho Ketsueki; 2007 Jul; 48(7):547-53. PubMed ID: 17695303
[TBL] [Abstract][Full Text] [Related]
14. Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARalpha rearrangement in newly diagnosed AML. The Medical Research Council (MRC) Adult Leukaemia Working Party.
Allford S; Grimwade D; Langabeer S; Duprez E; Saurin A; Chatters S; Walker H; Roberts P; Rogers J; Bain B; Patterson K; McKernan A; Freemont P; Solomon E; Burnett A; Goldstone A; Linch D
Br J Haematol; 1999 Apr; 105(1):198-207. PubMed ID: 10233384
[TBL] [Abstract][Full Text] [Related]
15. Contrasting antigenic maturation patterns in M0-M2 versus M3 acute myeloid leukemias.
Lewis RE; Cruse JM; Webb RN; Sanders CM; Beason K
Exp Mol Pathol; 2007 Oct; 83(2):269-73. PubMed ID: 17603036
[TBL] [Abstract][Full Text] [Related]
16. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML).
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Kroell T; Pfister K; Schmetzer H
Ann Hematol; 2005 May; 84(5):287-97. PubMed ID: 15592672
[TBL] [Abstract][Full Text] [Related]
17. Cell markers in the recognition of acute myeloblastic leukaemia subtypes.
Andoljsek D; Preloznik Zupan I; Zontar D; Cernelc P; Mlakar U; Modic M; Pretnar J; Zver S
Cell Mol Biol Lett; 2002; 7(2):343-5. PubMed ID: 12097981
[TBL] [Abstract][Full Text] [Related]
18. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
19. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization.
Klaus M; Haferlach T; Schnittger S; Kern W; Hiddemann W; Schoch C
Cancer Genet Cytogenet; 2004 Nov; 155(1):47-56. PubMed ID: 15527902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
